Mirati

Mirati Therapeutics To Present At Guggenheim Healthcare Talks 2021 Oncology Days

Retrieved on: 
Thursday, February 4, 2021
KRAS, Mirati

SAN DIEGO, Feb. 4, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced they will participate in a fireside chat at the Guggenheim Healthcare Talks 2021 Oncology Days on Thursday, February 11th at 9:00 a.m. ET/6:00 a.m. PT.Dan Faga, Executive Vice President and Chief Operating Officer, will represent Mirati at the event.

Key Points: 
  • SAN DIEGO, Feb. 4, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced they will participate in a fireside chat at the Guggenheim Healthcare Talks 2021 Oncology Days on Thursday, February 11th at 9:00 a.m. ET/6:00 a.m. PT.Dan Faga, Executive Vice President and Chief Operating Officer, will represent Mirati at the event.
  • The webcast will be available through the "Investors" section of the Mirati website at https://ir.mirati.com/events-and-presentations/default.aspx , and a replay of the webcast will be made available for 90 days following the event.
  • Mirati Therapeutics (NASDAQ: MRTX) is a San Diego-based late-stage biotechnology company relentlessly focused on translating drug discovery and research into new treatments for patients by advancing and delivering novel therapeutics that target the genetic and immunologic drivers of cancer.
  • Adagrasib is an investigational small molecule and selective KRAS G12C inhibitor in clinical development as a monotherapy and in combinations.

Mirati Therapeutics To Participate In The 29th Annual Credit Suisse Virtual Healthcare Conference

Retrieved on: 
Thursday, November 5, 2020
KRAS, Mirati

SAN DIEGO, Nov. 5, 2020 /PRNewswire/ --Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced they will participate in a fireside chat at the 29th Annual Credit Suisse Virtual Healthcare Conference on Thursday, November 12, 2020 at 9:30 a.m. PT/12:30 p.m. ET.Dan Faga, Executive Vice President and Chief Operating Officer, will represent Mirati at the event.

Key Points: 
  • SAN DIEGO, Nov. 5, 2020 /PRNewswire/ --Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced they will participate in a fireside chat at the 29th Annual Credit Suisse Virtual Healthcare Conference on Thursday, November 12, 2020 at 9:30 a.m. PT/12:30 p.m. ET.Dan Faga, Executive Vice President and Chief Operating Officer, will represent Mirati at the event.
  • The webcast will be available through the "Investors" section of the Mirati website at https://ir.mirati.com/events-and-presentations/default.aspx , and a replay of the webcast will be made available for 90 days following the event.
  • Mirati Therapeutics (NASDAQ: MRTX) is a San Diego-based late-stage biotechnology company relentlessly focused on translating drug discovery and research into new treatments for patients by advancing and delivering novel therapeutics that target the genetic and immunologic drivers of cancer.
  • Adagrasib is an investigational small molecule and selective KRAS G12C inhibitor in clinical development as a monotherapy and in combinations.

Mirati Therapeutics Reports Third Quarter 2020 Financial Results And Recent Business Highlights

Retrieved on: 
Wednesday, November 4, 2020
Mirati

SAN DIEGO, Nov. 4, 2020 /PRNewswire/ --Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter ended September 30, 2020 and recent business highlights.

Key Points: 
  • SAN DIEGO, Nov. 4, 2020 /PRNewswire/ --Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter ended September 30, 2020 and recent business highlights.
  • "The third quarter was notable for significant progress and we have begun the fourth quarter with positive momentum.
  • Research and development expenses for the third quarter of 2020 were $79.9 million, compared to $47.4 million for the same period in 2019.
  • This press release contains forward-looking statements regarding the business of Mirati Therapeutics, Inc. ("Mirati").

Mirati Therapeutics Appoints Jenny Gizzi As Vice President, Human Resources

Retrieved on: 
Thursday, August 15, 2019
Articles, Economy, Mirati, Bristol-Myers Squibb, Gizzi, Analytics, Business

SAN DIEGO, Aug. 15, 2019 /PRNewswire/ --Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, announced the appointment of Jenny Gizzi as Vice President, Human Resources, reporting directly toCharles M. Baum, M.D., Ph.D., President and Chief Executive Officer.

Key Points: 
  • SAN DIEGO, Aug. 15, 2019 /PRNewswire/ --Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, announced the appointment of Jenny Gizzi as Vice President, Human Resources, reporting directly toCharles M. Baum, M.D., Ph.D., President and Chief Executive Officer.
  • In her role, Ms. Gizzi will be responsible for all aspects of the Company's human resources operations and strategy, including overseeing the planning, development, implementation and administration of Mirati's human resources programs.
  • She will also be responsible for long range human resources planning to assist Mirati with continued growth.
  • Ms. Gizzi joins Mirati Therapeutics with over 20 years of experience in human resources, most recently serving as the Head of Strategy & Operations, Business Insights and Analytics at Bristol-Myers Squibb.